Position in SCYX
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$2,211,955
New position
Shares Held
543,478
first reported quarter
Ownership
5.46%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#4
of 39 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Jun 30, 2026ADAGE CAPITAL PARTNERS GP, L.L.C. holds $373,675,487 across 10 Drug Manufacturers - Specialty & Generic names. SCYX ranks #10 (0.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | TAK |
Takeda Pharmaceutical Co Ltd
|
6,050,771 | $96,993,859 | |
| 2 | TEVA |
Teva Pharmaceutical Industries Ltd
|
2,360,728 | $79,981,464 | |
| 3 | ALKS |
Alkermes plc.
|
1,368,000 | $71,683,200 | |
| 4 | ELAN |
Elanco Animal Health Inc
|
1,456,569 | $35,846,163 | |
| 5 | AMLX |
Amylyx Pharmaceuticals, Inc.
|
1,900,000 | $34,124,000 | |
| 6 | LNTH |
Lantheus Holdings, Inc.
|
246,755 | $27,374,999 | |
| 7 | VTRS |
Viatris Inc
|
843,736 | $13,398,527 | |
| 8 | BIOA |
BioAge Labs, Inc.
|
300,000 | $7,353,000 |
All Filings in SCYX
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $2,211,955 | 543,478 | Shares | Sole | 2026-08-14 | |
| No filing history on record for this holder in this stock. | ||||||